Breyanzi Meets Primary Endpoint in Pivotal Trial for R/R CLL
Here is a brief preview of this blast: On Thursday, January 26, BMS announced (press release) that Breyanzi (CD19 CAR-T) has met its primary endpoint (CR) in the Ph1/2 TRANSCEND CLL 004 trial for patients with ≥3L CLL / SLL. Below, Celltelligence provides insights on Breyanzi's market opportunity for CLL, while discussing potential approval timelines in the US.